(Q37889264)

24 August 2017

1 reference

title

Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension (English)

1 reference

24 August 2017

arterial hypertension

0 references

author name string

Geoff Strange

1

1 reference

24 August 2017

Anne Keogh

2

1 reference

24 August 2017

Brad Dalton

3

1 reference

24 August 2017

Eli Gabbay

4

1 reference

24 August 2017

1 June 2011

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

3

1 reference

24 August 2017

253-263

1 reference

Role of ambrisentan in the management of pulmonary hypertension

24 August 2017

1 reference

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model

21 January 2018

1 reference

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension: a preliminary decision analysis

21 January 2018

1 reference

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.

21 January 2018

1 reference

Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.

21 January 2018

1 reference

Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study

21 January 2018

1 reference

Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension

21 January 2018

1 reference

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease

21 January 2018

1 reference

The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension

21 January 2018

1 reference

Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension

21 January 2018

1 reference

Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases

21 January 2018

1 reference

An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease

21 January 2018

1 reference

Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.

21 January 2018

1 reference

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

21 January 2018

1 reference

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life

21 January 2018

1 reference

Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.

21 January 2018

1 reference

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.

21 January 2018

1 reference

Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.

21 January 2018

1 reference

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

21 January 2018

1 reference

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension

21 January 2018

1 reference

Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data

21 January 2018

1 reference

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

21 January 2018

1 reference

Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension

21 January 2018

1 reference

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.11.26

1 reference

24 August 2017

1 reference